Merck’s deal for Terns sparks debate over a possible biotech bidding war
Source: BioPharma Dive - Latest News
Some investors and analysts believe the pharma’s $6.7 billion offer is justified given Terns’ recent stock run. Others are convinced a better proposal is coming.